656 related articles for article (PubMed ID: 28604255)
1. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study.
La Torre G; Saulle R; Unim B; Meggiolaro A; Barbato A; Mannocci A; Spadea A
Hum Vaccin Immunother; 2017 Aug; 13(8):1879-1883. PubMed ID: 28604255
[TBL] [Abstract][Full Text] [Related]
2. Vaccines for measles, mumps and rubella in children.
Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
[TBL] [Abstract][Full Text] [Related]
3. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
[TBL] [Abstract][Full Text] [Related]
4. Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden.
Gehrt L; Englund H; Laake I; Nieminen H; Möller S; Feiring B; Lahdenkari M; Trogstad L; Benn CS; Sørup S
Vaccine; 2024 Apr; 42(12):2955-2965. PubMed ID: 38508926
[TBL] [Abstract][Full Text] [Related]
5. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
Wellington K; Goa KL
Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.
Böttiger M; Christenson B; Strandell A; Romanus V
Dev Biol Stand; 1986; 65():37-43. PubMed ID: 3556776
[TBL] [Abstract][Full Text] [Related]
7. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
[TBL] [Abstract][Full Text] [Related]
8. Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers.
Hyle EP; Rao SR; Bangs AC; Gastañaduy P; Fiebelkorn AP; Hagmann SHF; Walker AT; Walensky RP; Ryan ET; LaRocque RC
JAMA Pediatr; 2020 Feb; 174(2):e194515. PubMed ID: 31816033
[TBL] [Abstract][Full Text] [Related]
9. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for measles, mumps and rubella in children.
Demicheli V; Jefferson T; Rivetti A; Price D
Cochrane Database Syst Rev; 2005 Oct; (4):CD004407. PubMed ID: 16235361
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
12. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
13. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
[TBL] [Abstract][Full Text] [Related]
14. Measles, mumps, rubella prevention: how can we do better?
Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
[TBL] [Abstract][Full Text] [Related]
15. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
Singh HK; Chiu YL; Wilkin T
AIDS Patient Care STDS; 2015 Sep; 29(9):461-4. PubMed ID: 26153909
[No Abstract] [Full Text] [Related]
16. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
Knutsson N; Jansson UB; Alm B
Vaccine; 2006 Jul; 24(31-32):5800-5. PubMed ID: 16765490
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
18. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
Heath TC; Burgess MA; O'Brien ED
Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
[No Abstract] [Full Text] [Related]
19. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
